Sugi Predict

Sugi Predict / Compounds / SCHEMBL976990

SCHEMBL976990

SCHEMBL976990

Nc1nc(F)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.76
▸ PNP P00491 1/20 0.76
▸ TP53 P04637 1/20 0.76
▸ HTT P42858 1/20 0.76
▸ PDE4D Q08499 1/20 0.76
▸ PDE3A Q14432 1/20 0.76
▸ SMN1; SMN2 Q16637 1/20 0.76
▸ RXFP1 Q9HBX9 1/20 0.76
▸ HIF1A Q16665 2/20 0.65
▸ NT5E P21589 1/20 0.65
▸ AHCY P23526 4/20 0.59
▸ ADRB1 P08588 1/20 0.57
▸ DNMT1 P26358 1/20 0.57
▸ PIM1 P11309 1/20 0.54
▸ CSNK2A2 P19784 1/20 0.54
▸ CSNK2B P67870 1/20 0.54
▸ CSNK2A1 P68400 1/20 0.54
▸ CSNK2A3 Q8NEV1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1470361 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL976991 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL15623873 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL5982283 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL5790133 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL5982273 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL23982169 1.00 LMNA (0.76) LMNAPNPTP53HTTPDE4D
SCHEMBL16178342 0.91 LMNA (0.63) LMNAPNPTP53HTTPDE4D
SCHEMBL16178343 0.91 LMNA (0.63) LMNAPNPTP53HTTPDE4D
SCHEMBL998385 0.90 PNP (0.78) LMNAPNPTP53HTTPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117757876-A Double-enzyme catalysis preparation method of 2' -deoxy-2-fluoroadenosine 上海合润远生物技术有限公司 2024-03-26 — — CN claimed
CN-117568426-A Method for synthesizing 2 '-fluoro-2' -deoxyadenosine by whole cell catalysis 武汉糖智药业有限公司 2024-02-20 — — CN claimed
CN-117467726-A Preparation method of purine nucleoside 天津凯莱英生物科技有限公司 2024-01-30 — — CN claimed
CN-117447532-A Purification method of 2 '-fluoro-2' -deoxyadenosine 江苏申基生物科技有限公司 2024-01-26 — — CN claimed
CN-115725676-A Enzymatic synthesis method of modified nucleoside 江苏海洋大学 2023-03-03 — — CN claimed
CN-111534493-B Purine nucleoside phosphorylase mutant, gene and application 浙江大学宁波理工学院 2022-03-29 — — CN claimed
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-01 — — US claimed
CN-112823000-A Small polymer carriers for agent delivery 联邦高等教育系统匹兹堡大学 2021-05-18 — — CN claimed
CN-111534493-A Purine nucleoside phosphorylase mutant, gene and application 浙江大学宁波理工学院 2020-08-14 — — CN claimed
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-30 — — US claimed
WO-2003035012-A2 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB RESEARCH FOUNDATION (US) 2003-05-01 — — WO claimed
EP-0715523-B1 PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY UAB RESEARCH FOUNDATION (US) 2002-12-18 — — EP claimed
US-6491905-B1 GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY THE UAB RESEARCH FOUNDATION 2002-12-10 — — US claimed
EP-1229040-A2 Nucleoside monophosphate derivative, a processor for their production and their use as immunosuppressive drugs Heidelberg Pharma Holding GmbH (DE) 2002-08-07 — — EP claimed
US-6372725-B1 VIRICIDES, ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION HEIDELBERG PHARMA HOLDING GMBH (DE) 2002-04-16 — — US claimed
EP-0817790-B1 SPECIFIC LIPID CONJUGATES OF NUCLEOSIDE DIPHOSPHATES AND THEIR USE AS DRUGS HEIDELBERG PHARMA HOLDING GMBH (DE) 2001-11-14 — — EP claimed
US-6025343-A Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs ROCHE DIAGNOSTICS GMBH (DE) 2000-02-15 — — US claimed
US-6017896-A Purine nucleoside phosphorylase gene therapy for human malignancy UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) 2000-01-25 — — US claimed
EP-0715523-A1 PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY THE UAB RESEARCH FOUNDATION (US) 1996-06-12 — — EP claimed
WO-1995007718-A2 PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY THE UAB RESEARCH FOUNDATION (US) 1995-03-23 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules PIK3CA, CHAMP1, TYMP LMNA 1794/4885PNP 4/4885TP53 1059/4885
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules PIK3CA, CHAMP1, TYMP LMNA 1794/4885PNP 4/4885TP53 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.